Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma
Carbonic anhydrase (CA, EC 4.2.1.1) IX is regarded as a tumour hypoxia marker and CA inhibitors have been proposed as a new class of antitumor agents, with one such agent in Phase II clinical trials. The expression of some CAs, in particular the isoforms CA IX and CA XII, has been correlated with tu...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-01-01
|
Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14756366.2017.1411350 |
id |
doaj-2ebfe3c48516407eaa04726555ea7539 |
---|---|
record_format |
Article |
spelling |
doaj-2ebfe3c48516407eaa04726555ea75392020-11-25T01:22:12ZengTaylor & Francis GroupJournal of Enzyme Inhibition and Medicinal Chemistry1475-63661475-63742018-01-0133123424010.1080/14756366.2017.14113501411350Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinomaLaura Lucarini0Lucia Magnelli1Nicola Schiavone2Alfonso Crisci3Alessio Innocenti4Luca Puccetti5Fabio Cianchi6Sara Peri7Claudiu T. Supuran8Laura Papucci9Emanuela Masini10University of FlorenceUniversity of FlorenceUniversity of FlorenceUniversity of FlorenceUniversity of FlorenceSan Lazzaro HospitalUniversity of FlorenceUniversity of FlorenceUniversity of FlorenceUniversity of FlorenceUniversity of FlorenceCarbonic anhydrase (CA, EC 4.2.1.1) IX is regarded as a tumour hypoxia marker and CA inhibitors have been proposed as a new class of antitumor agents, with one such agent in Phase II clinical trials. The expression of some CAs, in particular the isoforms CA IX and CA XII, has been correlated with tumour aggressiveness and progression in several cancers. The aim of this study was to evaluate the possibility that CA IX could represent a marker related to clear cell Renal Cell Carcinoma (ccRCC). Bcl-2 and Bax, and the activity of caspase-3, evaluated in tissue biopsies from patients, were congruent with resistance to apoptosis in ccRCCs with respect to healthy controls, respectively. In the same samples, the CA IX and pro-angiogenic factor VEGF expressions revealed that both these hypoxia responsive proteins were strongly increased in ccRCC with respect to controls. CA IX plasma concentration and CA activity were assessed in healthy volunteers and patients with benign kidney tumours and ccRCCs. CA IX expression levels were found strongly increased only in plasma from ccRCC subjects, whereas, CA activity was found similarly increased both in plasma from ccRCC and benign tumour patients, compared to healthy volunteers. These results show that the plasmatic level of CA IX, but not the CA total activity, can be considered a diagnostic marker of ccRCCs. Furthermore, as many reports exist relating CA IX inhibition to a better outcome to anticancer therapy in ccRCC, plasma levels of CA IX could be also predictive for response to therapy.http://dx.doi.org/10.1080/14756366.2017.1411350Carbonic anhydraseisoform IXtumoursclear cell renal cell carcinoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Laura Lucarini Lucia Magnelli Nicola Schiavone Alfonso Crisci Alessio Innocenti Luca Puccetti Fabio Cianchi Sara Peri Claudiu T. Supuran Laura Papucci Emanuela Masini |
spellingShingle |
Laura Lucarini Lucia Magnelli Nicola Schiavone Alfonso Crisci Alessio Innocenti Luca Puccetti Fabio Cianchi Sara Peri Claudiu T. Supuran Laura Papucci Emanuela Masini Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma Journal of Enzyme Inhibition and Medicinal Chemistry Carbonic anhydrase isoform IX tumours clear cell renal cell carcinoma |
author_facet |
Laura Lucarini Lucia Magnelli Nicola Schiavone Alfonso Crisci Alessio Innocenti Luca Puccetti Fabio Cianchi Sara Peri Claudiu T. Supuran Laura Papucci Emanuela Masini |
author_sort |
Laura Lucarini |
title |
Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma |
title_short |
Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma |
title_full |
Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma |
title_fullStr |
Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma |
title_full_unstemmed |
Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma |
title_sort |
plasmatic carbonic anhydrase ix as a diagnostic marker for clear cell renal cell carcinoma |
publisher |
Taylor & Francis Group |
series |
Journal of Enzyme Inhibition and Medicinal Chemistry |
issn |
1475-6366 1475-6374 |
publishDate |
2018-01-01 |
description |
Carbonic anhydrase (CA, EC 4.2.1.1) IX is regarded as a tumour hypoxia marker and CA inhibitors have been proposed as a new class of antitumor agents, with one such agent in Phase II clinical trials. The expression of some CAs, in particular the isoforms CA IX and CA XII, has been correlated with tumour aggressiveness and progression in several cancers. The aim of this study was to evaluate the possibility that CA IX could represent a marker related to clear cell Renal Cell Carcinoma (ccRCC). Bcl-2 and Bax, and the activity of caspase-3, evaluated in tissue biopsies from patients, were congruent with resistance to apoptosis in ccRCCs with respect to healthy controls, respectively. In the same samples, the CA IX and pro-angiogenic factor VEGF expressions revealed that both these hypoxia responsive proteins were strongly increased in ccRCC with respect to controls. CA IX plasma concentration and CA activity were assessed in healthy volunteers and patients with benign kidney tumours and ccRCCs. CA IX expression levels were found strongly increased only in plasma from ccRCC subjects, whereas, CA activity was found similarly increased both in plasma from ccRCC and benign tumour patients, compared to healthy volunteers. These results show that the plasmatic level of CA IX, but not the CA total activity, can be considered a diagnostic marker of ccRCCs. Furthermore, as many reports exist relating CA IX inhibition to a better outcome to anticancer therapy in ccRCC, plasma levels of CA IX could be also predictive for response to therapy. |
topic |
Carbonic anhydrase isoform IX tumours clear cell renal cell carcinoma |
url |
http://dx.doi.org/10.1080/14756366.2017.1411350 |
work_keys_str_mv |
AT lauralucarini plasmaticcarbonicanhydraseixasadiagnosticmarkerforclearcellrenalcellcarcinoma AT luciamagnelli plasmaticcarbonicanhydraseixasadiagnosticmarkerforclearcellrenalcellcarcinoma AT nicolaschiavone plasmaticcarbonicanhydraseixasadiagnosticmarkerforclearcellrenalcellcarcinoma AT alfonsocrisci plasmaticcarbonicanhydraseixasadiagnosticmarkerforclearcellrenalcellcarcinoma AT alessioinnocenti plasmaticcarbonicanhydraseixasadiagnosticmarkerforclearcellrenalcellcarcinoma AT lucapuccetti plasmaticcarbonicanhydraseixasadiagnosticmarkerforclearcellrenalcellcarcinoma AT fabiocianchi plasmaticcarbonicanhydraseixasadiagnosticmarkerforclearcellrenalcellcarcinoma AT saraperi plasmaticcarbonicanhydraseixasadiagnosticmarkerforclearcellrenalcellcarcinoma AT claudiutsupuran plasmaticcarbonicanhydraseixasadiagnosticmarkerforclearcellrenalcellcarcinoma AT laurapapucci plasmaticcarbonicanhydraseixasadiagnosticmarkerforclearcellrenalcellcarcinoma AT emanuelamasini plasmaticcarbonicanhydraseixasadiagnosticmarkerforclearcellrenalcellcarcinoma |
_version_ |
1725127102848565248 |